WEBULL
WebtradeDownload

Is Teleflex (TFX) A Bargain On Its Dynetic 35 Showcase Plans?

Simply Wall St · 1d ago

Teleflex (TFX) is back in focus after announcing plans to showcase its Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen, supported by data from the BIONETIC-TRA study.

Teleflex shares have been relatively firm in 2026, with a year to date share price return of 13.04% despite a recent 1 day dip of 1.14% and 7 day decline of 0.94%. The 1 year total shareholder return of 7.04% contrasts with a much weaker 3 and 5 year total shareholder return, suggesting recent momentum is improving from a challenging longer term track record as investors weigh product launches, portfolio changes and lowered guidance.

Compare Teleflex with other medical device stocks that also show steady fundamentals and recent price interest by reviewing the hand picked list of solid balance sheet and fundamentals (53 results).

Teleflex has a long history in single use medical devices and a fresh product story with Dynetic 35 and recent portfolio moves. After this rebound in the share price, is the stock actually priced reasonably today?

Most Popular Narrative: 9.9% Undervalued

The most followed Teleflex valuation narrative places fair value at $153.55 compared with the last close at $138.36. That gap rests on a detailed view of margins, growth and capital deployment.

The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.

Read the complete narrative. Read the complete narrative.

Analysts behind this Teleflex narrative are not just plugging in simple growth rates. They are combining modest top line assumptions, a sharp inflection in profitability and a specific future earnings multiple. Curious which financial levers matter most for that fair value story?

Result: Fair Value of $153.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to factor in real pressure points for Teleflex, including weakness in UroLift and the execution risk around integrating the Biotronik Vascular Interventions business.

Find out about the key risks to this Teleflex narrative.

Another View on Teleflex Valuation

The SWS DCF model also points to Teleflex trading below an estimated future cash flow value of $260.32 compared with the current share price of $138.36. That is a wide gap for a company that is still loss making today. How comfortable are you with the cash flow path that needs to fill it?

To understand how this cash flow based view is built and what assumptions drive it, take a closer look at the valuation work behind the SWS DCF model. Look into how the SWS DCF model arrives at its fair value.

TFX Discounted Cash Flow as at Sep 2026
TFX Discounted Cash Flow as at Sep 2026

Next Steps

With mixed signals around Teleflex in this article, it makes sense to look at the underlying data yourself and decide where you stand. To weigh both sides of the story in one place, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Teleflex?

If Teleflex has you thinking harder about your portfolio, do not stop here. A few minutes with focused stock lists could surface ideas you will not want to miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.